All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019

Vasiliki-Kalliopi Bournia,1,2 George E Fragoulis,1 Panagiota Mitrou,1 Konstantinos Mathioudakis,3 Anastasios Tsolakidis,3 George Konstantonis,1 Georgia Vourli,4 Dimitrios Paraskevis,4 Maria G Tektonidou,4,5 Petros P Sfikakis1

ABSTRACT
Objectives To compare current all-cause mortality rates in rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) versus general population.

Methods In this population-based, retrospective cohort study, anonymised data on 11 186 586 citizens, including all patients with RA (42 735, 79% female), AS (9707, 43% female), PsA (13 779, 55% female), SLE (10 440, 89% female) and SSc (2277, 88% female), (median age of 64/47/54/53/59 years at study entry, respectively), were extracted from the electronic database covering nearly 99% of the Greek population.

Results After 1:5 (patients:general population) matching for gender/age, we found that survival was worse in SSc, followed by SLE and inflammatory arthritis. Compared with the general population HRs for death increased from the first 3 years to 5 years of observation possibly due to increases in disease duration: RA (from 0.63 to 1.13 (95% CI: 1.05 to 1.22), AS (from 0.62 to 1.01, (95% CI: 0.76 to 1.33), PsA (from 0.68 to 1.06, (95% CI: 0.88 to 1.28)), SLE (from 1.52 to 1.98, (95% CI: 1.67 to 2.33)) and SSc (from 2.27 to 4.24, (95% CI: 3.19 to 5.63)). In both SLE and SSc mortality was increased in men than women and in patients younger than 50 years.

Conclusions Survival rates over 5 years in inflammatory arthritis under treatment are currently becoming comparable (AS/PsA) or slightly higher (RA) than those of the general population. However, all-cause mortality is almost twofold and fourfold higher in SLE and SSc, respectively, being even higher for male and younger patients.

INTRODUCTION
It is common knowledge that systemic rheumatic diseases are characterised by increased morbidity and mortality.1,2 In addition to disease-specific factors and iatrogenic damage (eg, drug-related side effects), this, could be associated with comorbid cardiovascular disease, malignancy and increased risk for infections.3–6 Mortality risk is largely different among various rheumatic diseases,3,5–6 due to diverse underlying pathogenetic mechanisms and the degree of vital organ involvement, but also due to different therapeutic regimes used, and different age onset of each disease. However, change in mortality rates...
over time is dynamic, and certain aspects, in addition
to variances in treatment, need to be considered. For
example, different classification criteria used and/or the
availability or introduction of novel diagnostic tests might
affect the incidence of the index diseases. Moreover, over
the last decades, clinics dedicated to a specific disease are
becoming more common in many countries. This might
associate with selection bias, reporting patients with more
severe disease.12–15

Over the last years, the ‘treat-to-target’ approach gained
ground in the field of rheumatic diseases and especially
in inflammatory arthritis.10 11 One could hypothesise
that this strategy, along with the new therapeutic options
introduced and the better control of comorbidities, may
have led to decrease in the mortality rate of patients with
systemic rheumatic diseases. In this setting, many studies—
most of them in rheumatoid arthritis (RA)—have shown
that the gap of excess mortality risk, compared with
general population, is steadily closing.12–15 Of note, the
majority of these studies are based on data derived from
large registries5 7 14 15 and only few, reporting for systemic
sclerosis (SSc) up to 201515 and for systemic lupus erythe-
omas (SLE) up to 2013,9 are population studies.

Since 2011 our country operates an electronic data-
base for Social Security Services covering 99% of the
Greek population and holding information regarding
all prescriptions and their status (executed or not), all
medical diagnoses according to the specific International
Classification of Disease (ICD)-10, as well as all diagnostic
procedures ordered by physicians either in relation with
a specific condition or for presymptomatic testing. Given
that both Greek citizens and legal immigrants living in
Greece acquire free access to presymptomatic testing and
vaccinations through the electronic database for
Social Security Services, this database holds the records
of nearly every person in the country, irrespective of
health status. Furthermore, the database is linked via a—
specific for each patient—number with the nationwide
death records. Using this electronic database, we aimed
to assess the mortality rates in RA, ankylosing spondyl-
itis (AS), psoriatic arthritis (PsA), SLE and SSc patients
under treatment in comparison with the general popula-
tion free of these diseases between 2015 and 2019.

PATIENTS AND METHODS
In this nationwide, population based, retrospective,
matched cohort study, we searched the electronic
prescription database of the e-Government Center for
Social Security Services (IDIKA), to capture all patients
aged 18 years or older with RA, AS, PsA, SLE and SSc
under prescribed disease-specific treatment in Greece,
who filled at least one prescription for any drug listed
below, between 1 January 2015 and 31 December 2019.
We used predefined ICD-10 codes for RA, AS, PsA, SLE
and SSc, in order to capture all patients who filled a
prescription for any of the following drugs: conventional
synthetic Disease Modifying Anti-Rheumatic Drugs [(cs
DMARDs] (sulfasalazine, methotrexate, azathioprine,
leflunomide, ciclosporin, D-penicillamine, hydroxychlo-
roquine, cyclophosphamide, mycophenolic acid), corti-
costeroids (betamethasone, dexamethasone, fluocorto-
lone, methylprednisolone, paramethasone, prednisol-
one, prednisone, rimexolone, hydrocortisone, corti-
zone, prednylidene, deflazacort, cloprednol, meprednisone, cortizavol), biological (b)DMARDs (abat-
acet, tocilizumab, anakinra, ustekinumab, secukinumab,
rituximab, adalimumab, certolizumab pegol, etanercept,
golimumab, infliximab, belimumab), targeted synthetic
t(s)DMARDs (tocafitinib, upadacitinib, baricitinib,
apremilast), advanced vasodilatory therapy (bosentan,
ambrisentan, sitaxentan, macitentan, riociguat, tadalafil,
sildenafil, vardenafil, avanafil, udenafil), epoprostenol,
ambrisentan, sitaxentan, macitentan, rituximab, adalimumab,
cyclophosphamide, mycophenolic acid), corti-
costeroids (betamethasone, dexamethasone, fluocorto-
lone, methylprednisolone, paramethasone, prednisol-
one, prednisone, rimexolone, hydrocortisone, corti-
zone, prednylidene, deflazacort, cloprednol, meprednisone, cortizavol), biological (b)DMARDs (abat-
acet, tocilizumab, anakinra, ustekinumab, secukinumab,
rutuximab, adalimumab, certolizumab pegol, etanercept,
golimumab, infliximab, belimumab), targeted synthetic
t(s)DMARDs (tocafitinib, upadacitinib, baricitinib,
apremilast), advanced vasodilatory therapy (bosentan,
ambrisentan, sitaxentan, macitentan, riociguat, tadalafil,
sildenafil, vardenafil, avanafil, udenafil, epoprostenol,
ilprost, beraprost, treprostinil, selexipag) and anti-
fibrotic therapy (nintedanib, pirfenidone) (see online
supplemental tables 1 and 2 for an extensive list of ICD-10 and
ATC5 codes, respectively). For the few patients (1.97%
who had filled consecutive prescriptions with more
than one ICD-10 codes, we arbitrarily accepted the most
recently used ICD-10 code to define diagnosis. The date
when each patient filled the first prescription for one of
the above-mentioned medications of interest, with one of

| Table 1 | Demographics at study entry of patients with RA, AS, PsA, SLE, SSc and age-matched and gender-matched individuals from the general population free of systemic rheumatic disease |
|---------|-------------------------------------------------------------------------------------------------|
| RA      | [Patients | General population | AS | Patients | General population | PsA | Patients | General population | SLE | Patients | General population | SSc | Patients | General population |
| N       | 42 735 | 213 675 | 9707 | 48 535 | 13 779 | 68 895 | 10 440 | 52 200 | 2277 | 11 385 |                                       |
| Female gender (N (%)) | 33 641 (79) | 168 205 (79) | 4163 (43) | 20 815 (43) | 7565 (55) | 37 825 (55) | 9315 (89) | 46 575 (89) | 1998 (88) | 9990 (88) |                                       |
| Median (IQR) age in years | 64 (54–73) |                                           | 47 (38–56) |                                                   | 54 (45–64) |                                          | 53 (42–64) |                                         | 59 (49–68) |                                         |

AS, ankylosing Spondylitis; N, number; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
Connective tissue diseases

the diagnoses under study was defined as date of entry in the cohort.

For this 5-year period (2015–2019), the IDIKA database holds the prescription records of 11 186 586 citizens. To avoid selection bias, in our cohort, all patients with disease-specific prescribed medication were included, based on ICD-10 codes. Patients buying their rheumatology drugs over the counter are not captured, however, the percentage of patients acquiring their medication without prescription for five consecutive years should be too low to have significantly affected our results. Patients were randomly matched for gender and year of birth (individual matching 1:5) to individuals from the general population free of RA, AS, PsA, SLE and SSc, who had a valid social security number during the same period of time. For all subjects free of systemic rheumatic disease the date of entry in the cohort was selected to match that of their index patient. Here forth, all exposed subjects in our cohort will be referred to as patients and all unexposed subjects will be referred to as general population. For all study participants, we were able to record the date of birth, gender, as well as vital status and date of death between 1 January 2015 and 31 December 2019. Our study did not extend beyond 31 December 2019 to avoid recording any possible effects of the COVID-19 pandemic on the survival of patients with rheumatic diseases.

The primary outcome of the study was the assessment of all-cause mortality in patients with RA, AS, PsA, SSc and SLE compared with the general population.

Statistics

Survival time was estimated from the time of entry in the cohort until the event of interest (death from all causes), or until administrative censoring if the event was not observed. Three-year and 5-year survival of patients with RA, AS, PsA, SLE and SSc and their age and gender matched counterparts derived from the general population was estimated by Kaplan-Meier analysis, while differences were assessed by the Log Rank test. Graphs are presented using a time scale in years (12 month-intervals). Cox regression model was used to evaluate the effect of each systemic rheumatic disease on death from all causes. The proportional hazards assumption was tested using Schoenfeld residuals and graphically assessed using -log(log(S(t))) graph. To account for the violations of the proportional hazards assumption, an interaction of each disease with time was allowed. For this purpose, a cut-off of 36 months was used. Therefore, HRs are presented separately for the time period prior to and following 36 months. A subgroup analysis was performed based on patient gender and age, using 50 years at cohort entry as a cut-off. This cut-off was selected as it represents the median age of the adult population included in the prescription database. There were no missing data on covariates we selected to record. Multivariable analysis was not possible due to lack of data on disease duration, disease severity, socioeconomic status, comorbidities, smoking status. Statistical analysis was performed using the Stata statistical software package (StataCorp. 2013. Stata Statistical Software: Release V.13, StataCorp.)
RESULTS

Patient demographics

As shown in table 1 our search of the database revealed 42,735 patients with RA (79% female), 9,707 patients with AS (43% female), 13,779 patients with PsA (55% female), 10,440 patients with SLE (89% female) and 22,777 patients with SSc (88% female). These were randomly matched to 394,690 subjects from the general population of the same age and gender, using a 1:5 ratio. Patients with RA were older compared with other patient groups, with a median (IQR) age of 64 (54–73) years, followed by patients with SSc, PsA, SLE and AS, with a median (IQR) age of 59 (49–68), 54 (45–64), 53 (42–64) and 47 (38–56) years, respectively.

Survival analysis in the entire population

During the study period, there were 582,551 deaths documented in the database, of which 27,252 among RA (death rate (95% CI): 19.07 (18.37 to 19.80) per 1000 RA patient-years) 150 among AS (death rate (95% CI): 4.57 (3.89 to 5.36) per 1000 AS patient-years) 376 among PsA (death rate (95% CI): 2.27 (1.89 to 2.74) per 1000 AS patient-years) 1,521 among SLE (death rate (95% CI): 15.00 (13.83 to 16.26) per 1000 SLE patient-years) and 2,774 among SSc (death rate (95% CI): 7.82 (7.43 to 8.21) per 1000 SSc patient-years); these were randomly matched to 394,690 subjects from the general population of the same age and gender, using a 1:5 ratio. Patients with RA were older compared with other patient groups, with a median (IQR) age of 64 (54–73) years, followed by patients with SSc, PsA, SLE and AS, with a median (IQR) age of 59 (49–68), 54 (45–64), 53 (42–64) and 47 (38–56) years, respectively.

The average effect of underlying systemic rheumatic disease on patient survival is shown in table 2, which indicates that the average risk of death from all causes over the 5-year follow-up period was lower for RA (HR: 0.74, (95% CI: 0.71 to 0.77)), AS (HR: 0.62, (95% CI: 0.62 to 0.87)) and PsA (HR: 0.78, (95% CI: 0.70 to 0.87)) patients compared with the general population, whereas for SLE (HR: 1.65, (95% CI: 1.50 to 1.81)) and SSc (HR: 2.72, (95% CI: 2.33 to 3.17)) patients it was higher.

After testing for proportionality, we found that the risk of death from all causes changed over time, therefore, an interaction with time was allowed. As shown in table 3, the HR for the effect of RA during the first 3 years of follow-up was 0.63 (95% CI: 0.60 to 0.66), increasing to 1.13 (95% CI: 1.05 to 1.22) in the next 2 years, due to the interaction effect. Likewise, the HR for the effect of AS and PsA on death from all causes was 0.64 (95% CI: 0.50 to 0.77) and 0.68 (95% CI: 0.59 to 0.78), for the first 3 years, respectively, becoming comparable to that of the general population in the following 2 years (1.01 (95% CI: 0.76 to 1.33) and 1.06 (95% CI: 0.88 to 1.28), for AS and PsA, respectively). On the other hand, the HR for the effect of SLE and SSc was 1.32 (95% CI: 1.30 to 1.35) in the next 2 years.

for subjects matched to SLE, and 12.45 (11.40 to 13.59) per 1000 person-years for subjects matched to SSc. Kaplan-Meier survival curves for RA, AS, PsA, SSc, SLE patients and for age and gender matched subjects from the general population, entered in our study between 1 January 2015 and 31 December 2019 are shown in figure 1. Three-year and 5-year survival rates are presented in online supplemental table 4. As shown from the plots patients with SSc have the worse survival, followed by patients with SLE and patients with inflammatory arthritis.

Assuming proportionality of HRs over time, we performed Cox regression analysis comparing the risk of death between each group of systemic rheumatic disease patients and age-matched and gender-matched individuals derived from the general population, free of systemic rheumatic disease. The average effect of underlying systemic rheumatic disease on patient survival is shown in table 2, which indicates that the average risk of death from all causes over the 5-year follow-up period was lower for RA (HR: 0.74, (95% CI: 0.71 to 0.77)), AS (HR: 0.62, (95% CI: 0.62 to 0.87)) and PsA (HR: 0.78, (95% CI: 0.70 to 0.87)) patients compared with the general population, whereas for SLE (HR: 1.65, (95% CI: 1.50 to 1.81)) and SSc (HR: 2.72, (95% CI: 2.33 to 3.17)) patients it was higher.

After testing for proportionality, we found that the risk of death from all causes changed over time, therefore, an interaction with time was allowed. As shown in table 3, the HR for the effect of RA during the first 3 years of follow-up was 0.63 (95% CI: 0.60 to 0.66), increasing to 1.13 (95% CI: 1.05 to 1.22) in the next 2 years, due to the interaction effect. Likewise, the HR for the effect of AS and PsA on death from all causes was 0.64 (95% CI: 0.50 to 0.77) and 0.68 (95% CI: 0.59 to 0.78), for the first 3 years, respectively, becoming comparable to that of the general population in the following 2 years (1.01 (95% CI: 0.76 to 1.33) and 1.06 (95% CI: 0.88 to 1.28), for AS and PsA, respectively). On the other hand, the HR for the effect of SLE and SSc was 1.32 (95% CI: 1.30 to 1.35) in the next 2 years.

Table 3 HR, with 95% CI and p values, for the effect of RA, AS, PsA, SLE and SSc on all-cause mortality of the entire patient cohort for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

| Variable | Entire cohort, 0–36 months of follow-up | Entire cohort, >36 months of follow-up |
|----------|--------------------------------------|--------------------------------------|
| HR (main effect) | 95% CI | P value | HR (main effect) | 95% CI | P value |
| RA | 0.63 | 0.60 to 0.66 | <0.001 | 1.13* | 1.05 to 1.22 | 0.002 |
| AS | 0.62 | 0.50 to 0.77 | <0.001 | 1.01** | 0.76 to 1.33 | 0.958 |
| PsA | 0.68 | 0.59 to 0.78 | <0.001 | 1.06* | 0.88 to 1.28 | 0.537 |
| SLE | 1.52 | 1.35 to 1.70 | <0.001 | 1.98** | 1.67 to 2.33 | <0.001 |
| SSc | 2.27 | 1.89 to 2.74 | <0.001 | 4.24* | 3.19 to 5.63 | <0.001 |

P value for interaction *<0.001; **<0.05.

AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
Higher risk of death in male versus female patients with SLE and SSc

To investigate the effect of gender on all-cause mortality of patients with systemic rheumatic diseases we performed a subgroup analysis in male and female patient subsets. Figure 2 shows Kaplan-Meier survival analysis in male and female study participants. As seen from the curves, male SLE and SSc patients fare considerably worse compared with their female counterparts.

When Cox regression models were used, the assumption of proportionality of hazards was maintained for female patients with AS and for male patients with SLE, but was violated for all other patient subgroups, necessitating the introduction of an interaction term with time in the respective analysis. Our results (table 4) indicated that the effect of SLE was slightly more pronounced among male patients compared with females for the first 3 years of follow-up. In fact, the HR for the effect of SLE on death from all causes during the first 3 years was 1.91 (95% CI: 1.56 to 2.35) among male patients, compared with 1.47 (95% CI: 1.29 to 1.67) among female patients.

A marginal difference between male and female patients could also be seen for the effect of SSc on all-cause mortality after the first 3 years of follow-up. More specifically, the HR for the effect of SSc on all-cause mortality was similar for males (2.56 (95% CI: 1.57 to 4.16)) and females (2.23 (95% CI: 1.83 to 2.72)) up to the first 3 years, increasing to 7.28 (95% CI: 3.30 to 16.06) and 3.90 (95% CI: 2.87 to 5.29) for males and females, respectively, thereafter. Differences between genders in other rheumatic diseases were not so pronounced.

Highest risk of death in patients with SLE and SSc younger than 50 years

In a second subgroup analysis, we assessed the risk of death from all causes in the group of study participants aged under 50 years and in those aged 50 years or older at cohort entry. Kaplan-Meier survival curves are shown in figure 3. As expected, older patients had worse survival across all systemic rheumatic diseases, which was more pronounced in SLE and SSc. In Cox regression analysis, violation of the proportionality assumption was found for both subgroups of patients with RA and for the subgroups of AS, SpA, SLE and SSc patients aged 50 years and older, in which cases an interaction term was added in the model. Our findings (table 5) clearly indicate that the effect of SLE on all-cause mortality was more pronounced among younger patients, an observation which was also true for younger patients with SSc during the first 3 years of follow-up. More specifically, the HR for death from all causes for patients with SLE and SSc <50 years was 2.74 (95% CI: 1.92 to 3.92) and 5.18 (95% CI: 2.71 to 9.89), respectively. In comparison, the initial HR for the effect of SLE and SSc on the survival of patients ≥50 years of age was 1.47 (95% CI: 1.30 to 1.66) and 2.20 (95% CI: 1.82 to 2.66), respectively, during the first 3 years of follow-up, but further increased to 1.89 (95% CI: 1.59 to 2.25) and 4.01 (95% CI: 3.00 to 5.37) respectively, during the subsequent 2 years of follow-up, due to interaction with time.

In contrast, the HR for the effect of the inflammatory arthritides on all-cause mortality seemed to favour the younger patient population, at least for the last 2 years of follow-up. More specifically, after the third year of follow-up, the HR for the effect of RA on death from all causes was 1.12 (95% CI: 1.04 to 1.21) in the older patient
subgroup, whereas it was non-significant in the younger patient subgroup. Likewise, during the last 2 years of follow-up, the HR for the effect of AS and PsA on death from all causes was 0.57 (95% CI: 0.33 to 0.96) and 0.52 (95% CI: 0.28 to 0.95) among younger patients, but it was non-significant among older patients. A less pronounced effect of disease on all-cause mortality among younger individuals was also seen for PsA during the first 3 years of follow-up (HR: 0.52 (95% CI: 0.28 to 0.95) for the younger group vs 0.69 (95% CI: 0.60 to 0.79) in the older group).

**DISCUSSION**

Herein, using data on more than 11 million people during 2015–2019, we show that current mortality risk is much higher for SLE and SSc and especially for male and younger patients, compared with the general population. In contrast, we show that mortality rates in patients under treatment for inflammatory arthritis are slightly higher (for RA) or comparable (for AS and PsA) to the general population. This possibly reflects that newer strategies (eg, treat-to-target) are more effective in the control of inflammation, also affecting mortality.

As regards to SLE, in the largest study so far examining all US residents, however, based only on death certificates from the national mortality database and census data, it was found that SLE mortality decreased over the last 50 years (1968–2013) but still remained higher compared with the general population. In fact, an inverted U-shape distribution was observed for SLE mortality in this study, resulting in sustained decrease over the last decades. Another study, following-up about 1700 patients with SLE in Toronto lupus clinic between 1971 and 2013, showed that mortality rate was dramatically decreased over the last years, remaining higher though compared with the general population; in accordance with our findings, mortality risk was much higher in younger people (age <40 years old). As regards to SSc, data are even more limited. In the largest cohort study so far, mortality rates increased during 1968–2000, but decreased each year thereafter till 2015, while in a recent meta-analysis, standardised mortality ratio (SMR) in SSc was found about 3.5. In a relatively large cohort of SSc patients, it was shown that mortality is more pronounced in patients with early disease.

As regards to inflammatory arthritis, in previous decades, it was clear that patients with RA had higher mortality compared with the general population. Despite some disagreements, it seems that this gap is gradually closing. A large study from the UK, examining data obtained between 1994 and 2010, compared patients with RA to the general population and showed an increased mortality. In another study examining mortality rates in Canada, investigators showed that mortality in RA decreased over time, but remained higher compared with the general population. Contrary, other studies have shown that over the last years there is an improving trend in RA mortality. In fact, it has been suggested that all-cause mortality is improved to a greater degree in patients with RA compared with the general population. Provan et al showed that all-cause and CVD mortality was increased for patients with RA up to 2004 but not after this date. Similarly, another group showed that mortality was increased for RA, in patients diagnosed from 1996 to 2000, but not after that time point. The more recent large study using data from a Danish registry showed that all-cause mortality was similar between RA and general population, despite the fact that cardiac deaths and major adverse cardiovascular events were more common in the former.

Several characteristics could affect mortality rates in RA. In general, mortality seems to be increased in established

---

**Table 4** HR, with 95% CI and p values, for the effect of RA, AS, PsA, SLE and SSc on all-cause mortality of male and female patients for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

| Systemic rheumatic disease | Gender | 0–36 months of follow-up | >36 months of follow-up |
|---------------------------|--------|------------------------|------------------------|
|                           |        | HR (main effect)       | HR (main effect)       |
|                           |        | 95% CI                 | P value                |
|                           |        |                        |                        |
| RA                        | Male   | 0.6                    | 1.13*                  |
|                           | Female | 0.65                   | 1.13*                  |
| AS                        | Male   | 0.61                   | 1.06**                 |
|                           | Female | 0.7                    | 0.7                    |
| PsA                       | Male   | 0.68                   | 0.94**                 |
|                           | Female | 0.69                   | 1.22*                  |
| SLE                       | Male   | 1.91                   | 1.91                   |
|                           | Female | 1.47                   | 1.87**                 |
| SSc                       | Male   | 2.56                   | 7.28**                 |
|                           | Female | 2.23                   | 3.90**                 |

P value for interaction *<0.001; **<0.05.

AS, Ankylosing Spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
compared with early RA, possibly due to accumulated comorbidities and chronic inflammation. A recent study of patients with early RA but a long follow-up (ie, 23 years), enrolling low number of patients though, showed that mortality in RA was comparable to the general population. Seeing the other flip of the coin, disease duration might negatively affect the observed mortality. In an inception RA cohort, with a long follow-up, differences between observed and expected mortality emerged after 10 years of follow-up. Along the same lines, in data obtained from a Swedish registry for early RA, it was found that excess mortality for individuals with RA compared with comparators from general population appeared 5 years after disease diagnosis. Finally, data from WHO have shown that although RA excess mortality is declining over time, there are significant disparities between countries.

As regards to spondylarthritis (SpA), the classification criteria introduced in the last decade have made comparisons between the few relevant studies conducted at different time points difficult. This is due to the fact that many different subcategories of diseases, like PsA or AS are classified under the SpA umbrella. Data for AS are indeed limited. However, there is evidence that mortality has improved over the last years. Herein, we clearly show that death risk for patients with AS under treatment is decreased compared with the general population. Importantly, 88% of our patients with AS were on treatment with biologics, thus on a better control of their disease. On the other hand, we were not able to examine whether there is some risk for specific causes of death, like infections, as has been shown by others. As regard to PsA, one study of about 8500 patients incorporating data obtained between 1994 and 2010, showed that irrespective of treatment received, patients with PsA did not display higher mortality compared with the general population or increased rates of cause-specific death. In contrast, another population-based study enrolling 40% of the total population of Canada, found that SMR for psoriasis and PsA decreased over the last twenty years (1996–2016) but was still higher compared with the general population. Also, age-specific SMR had an inverted U-shape distribution with mortality being higher in individuals aged between 50 and 59 years old. In contrast, herein we show that mortality risk in patients with PsA is lower than the general population for the first 3 years after disease diagnosis, becoming comparable to the general population thereafter. Plausible explanations for this disagreement are that our study used different entry criteria and also examines data between 2015 and 2019, during which time two-thirds of patients are being treated with biologics. Other smaller-scale studies clearly show that mortality in PsA is improving over calendar years.

Our study has specific strengths and limitations. The major strength is that the entire population of one country is included, avoiding thus selection bias. We also examine simultaneously five systemic rheumatic diseases within the same population, whereas mortality was recorded for 5 years (2015–2019). We opted to use the years 2015–2019, having in mind that COVID-19 pandemic might have affected the mortality in patients with systemic rheumatic diseases. Notably, a recent study has shown that the relative mortality risk for RA and other inflammatory arthritides in 2020, compared with general
population remained unchanged. On the other hand, we were not able to capture patients who did not have a prescription for their rheumatology drugs, but instead purchased their drugs over the counter; our unpublished data suggest that these individuals are few. In addition, misclassification can always be an issue in studies based on large prescription databases. To minimise this effect in our study we only selected patients under treatment with corticosteroids and/or DMARDs who had filled in their prescriptions. Also, we were not able to control for other confounders such as disease duration and severity, socioeconomic status, comorbidities, smoking or to perform analyses for cause-specific mortality. One should also be cautious in interpreting p values of Log-Rank tests in our study. The large number of patients included could have distorted the relationship between p values and the clinical relevance of the differences found.

Finally, due to the nature of our cohort (ie, not an inception cohort) criterion of proportionality regarding to the risk of death, was not fulfilled. In fact, we observed that the effect of all systemic rheumatic diseases examined on all-cause mortality increased over time, in parallel to the observation period/disease duration. This can be attributed to tighter control of disease closer to diagnosis and accumulation of comorbid conditions related or not to inflammation.

In conclusion, based on current data, all-cause mortality of patients who are treated for RA is almost comparable to the general population, whereas, for patients with spondyloarthopathies, mortality rates are in fact lower for the first 3 years of observation becoming similar to the general population thereafter. Availability of effective therapeutic options, treat-to-target strategies and perhaps better control of cardiovascular comorbidities over the last years might explain our results which pertain to calendar years 2015–2019. Similar strategies could be adopted for the other systemic rheumatic diseases as well. As shown in other studies as well, disease duration seems to negatively affect mortality in all systemic rheumatic diseases, leading to slightly increased mortality risk for RA and to abolishment of reduced mortality for SpA, 3 years after disease diagnosis. Male gender and younger age in SLE and SSc are adverse prognostic factors, highlighting that these patients need closer follow-up and more effective treatments.

Table 5  HR, with 95% CI and p values, for the effect of RA, AS, PsA, SLE and SSc on all-cause mortality of patients <50 years and ≥50 years of age for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

| Systemic rheumatic disease | 0–36 months of follow-up | >36 months of follow-up |
|----------------------------|--------------------------|-------------------------|
|                            | HR (main effect)         | 95% CI                  | P value       | HR (main effect) | 95% CI                  | P value       |
| RA <50                     | 0.43                     | 0.28 to 0.69            | <0.001        | 1.36**          | 0.72 to 2.59            | 0.345         |
| ≥50                        | 0.63                     | 0.60 to 0.67            | <0.001        | 1.12*           | 1.04 to 1.21            | 0.002         |
| AS <50                     | 0.57                     | 0.33 to 0.96            | 0.037         | 0.57            | 0.33 to 0.96            | 0.037         |
| ≥50                        | 0.65                     | 0.52 to 0.83            | <0.001        | 1.04**          | 0.77 to 1.41            | 0.806         |
| PsA <50                    | 0.52                     | 0.28 to 0.95            | 0.036         | 0.52            | 0.28 to 0.95            | 0.036         |
| ≥50                        | 0.69                     | 0.60 to 0.79            | <0.001        | 1.08*           | 0.89 to 1.31            | 0.418         |
| SLE <50                    | 2.74                     | 1.92 to 3.92            | <0.001        | 2.74            | 1.92 to 3.92            | <0.001        |
| ≥50                        | 1.47                     | 1.30 to 1.66            | <0.001        | 1.89*           | 1.59 to 2.25            | <0.001        |
| SSc <50                    | 5.18                     | 2.71 to 9.89            | <0.001        | 5.18            | 2.71 to 9.89            | <0.001        |
| ≥50                        | 2.2                      | 1.82 to 2.66            | <0.001        | 4.01**          | 3.00 to 5.37            | <0.001        |

P value for interaction *<0.001; **<0.05.

AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
REFERENCES

1. Toledano E, Candelas G, Rosales Z, et al. A meta-analysis of mortality in rheumatic diseases. *Reumatol Clin* 2012;8:334–41.

2. Ziade N, El Khoury B, Zoghbi M, et al. Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORIS study. *Sci Rep* 2020;10:7683.

3. Colaco K, Widdifield J, Luo J, et al. Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. *J Am Acad Dermatol* 2021;84:1302–9.

4. Fragoulis GE, Chatziodionysiou K, Nikolopoulou E, et al. Damage Accrual in rheumatoid arthritis: evaluating the joint and beyond. *Arthritis Rheumatol* 2020;72:1967–70.

5. Ogdie A, Haynes K, Troxel AB, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. *Ann Rheum Dis* 2014;73:149–53.

6. Tsiloius K, Gladman DD, Sheane BJ, et al. All-Cause, cause-specific and age-specific standardized mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). *Ann Rheum Dis* 2019;78:802–8.

7. Ogdie A, Malha S, Shin D, et al. Cause-Specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. *Rheumatology* 2017;56:907–11.

8. Yen EY, Singh DR, Singh RR. Trends in systemic sclerosis mortality over Forty-Eight years, 1968–2015: a US Population-Based study. *Arthritis Care Res* 2021;73:1502–10.

9. Yen EY, Shaheen M, Woo JMF, et al. 46-Year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study. *Ann Intern Med* 2017;167:77–85.

10. Smolen JS, Ulmer B, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an International Task force. *Ann Rheum Dis* 2018;77:3–17.

11. Thomas K, Lazarini A, Kabourov K, et al. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. *Ther Adv Musculoskelet Dis* 2020;12:1759720X20937132.

12. Dabouin S, Zeboulou-Ktorza N, Combes G, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. *Joint Bone Spine* 2013;80:29–33.

13. Lacaille D, Avina-Zubieta JA, Sayre EC, et al. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. *Ann Rheum Dis* 2017;76:1057–63.

14. Logstrup BB, Ellingsen T, Pedersen AB, et al. Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. *Rheumatology* 2021;60:1400–9.

15. Zhang Y, Lu N, Peloquin C, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. *Ann Rheum Dis* 2017;76:408–13.

16. Elhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. *Rheumatology* 2012;51:1017–26.

17. Poole R, Nhlupumulo A, Dauchet L, et al. Survival and progression factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. *Rheumatology* 2017;56:399–407.

18. Hao Y, Hudson M, Baron M, et al. Early mortality in a multinational systemic sclerosis inception cohort. *Arthritis Rheumatol* 2017;69:1067–77.

19. Houge IS, Hoff M, Thomas R, et al. Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population - the Nord-Trøndelag Health Study. *Sci Rep* 2020;10:3593.

20. Abhishek A, Nakafero G, Kuo C-F, et al. Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from clinical practice research Datalink. *Rheumatology* 2018;57:977–81.

21. Widdifield J, Bernatsky S, Paterson JM, et al. Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. *Arthritis Care Res* 2015;67:1047–53.

22. Provant SA, Lillegraen S, Sexton J, et al. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. *Rheumatology* 2020;59:505–12.

23. Prati C, Claudepierres D, Nakafero G, et al. Improvement in life expectancy of patients with psoriatic arthritis and rheumatoid arthritis over Forty-Eight years, 1968–2015: a US Population-Based study. *Arthritis Care Res* 2014;73:149–53.

24. Radovits BJ, Fransen J, Al Shamma S, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. *Arthritis Res Ther* 2019;21:2010:362–70.

25. Holmqvist M, Ljung L, Askling J. Mortality following new-onset rheumatoid arthritis: has modern rheumatology had an impact? *Ann Rheum Dis* 2018;77:85–91.

26. Kiadaghi AA, Felton DT, Nofi J, et al. Brief report: rheumatoid arthritis as the underlying cause of death in Thirty-One countries, 1987–2011: trend analysis of World Health Organization mortality database. *Arthritis Rheumatol* 2017;69:1560–5.

27. Prati C, Claudepierres P, Pham T, et al. Mortality in spondylarthristis. *J Rheumatol* 2014;41:715–20.

28. Prati C, Puypevaux M, Guillot X, et al. Deaths associated with ankylosing spondylitis in France from 1969 to 2009. *J Rheumatol* 2017;44:594–8.

29. Ali Y, Tom BD, Schentag CT, et al. Improved survival in psoriatic arthritis with calendar time. *Arthritis Rheum* 2007;56:2708–14.

30. Elalouf O, Muntyanu A, Polacheck A, et al. Mortality in psoriatic arthritis: risk, causes of death, predictors for death. *Semin Arthritis Rheum* 2020;50:571–5.

31. Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. *Ann Rheum Dis* 2021. doi:10.1136/annrheumdis-2021-219845. [Epub ahead of print: 23 Feb 2021].